Biotech · Private company
Turning Point Therapeutics, Inc.
Track this companyFree. Adds Turning Point Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials93 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- Oral repotrectinib (TPX-0005)Phase 2 · Locally Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- TPX-0005Phase 2 · KRAS Mutation-Related TumorsClinicalTrials.gov · fetched Nov 12, 2026
- TPX-0046Phase 2 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- TrametinibPhase 2 · KRAS Mutation-Related TumorsClinicalTrials.gov · fetched Nov 12, 2026
- DigoxinPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- elzovantinib (TPX-0022)Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- LM-302Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Metformin HydrochloridePhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- repotrectinib (TPX-0005)Phase 1 · Locally Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Rosuvastatin CalciumPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- TPX-0005Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- TPX-0131Phase 1 · Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid TumorsPHASE1 · WITHDRAWN · started Nov 15, 2024ClinicalTrials.gov NCT05828303 · fetched Nov 12, 2026
- A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer PatientsPHASE1 · WITHDRAWN · started Jul 28, 2022ClinicalTrials.gov NCT05828277 · fetched Nov 12, 2026
- Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid TumorsPHASE1 · COMPLETED · started Dec 29, 2021ClinicalTrials.gov NCT05001516 · fetched Nov 12, 2026
- A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid TumorsPHASE1_PHASE2 · TERMINATED · started Sep 23, 2021ClinicalTrials.gov NCT05071183 · fetched Nov 12, 2026
- A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCPHASE1 · TERMINATED · started Jul 28, 2021ClinicalTrials.gov NCT04849273 · fetched Nov 12, 2026
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPHASE1_PHASE2 · RECRUITING · started Mar 12, 2020ClinicalTrials.gov NCT04094610 · fetched Nov 12, 2026
- Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsPHASE1_PHASE2 · TERMINATED · started Dec 6, 2019ClinicalTrials.gov NCT04161391 · fetched Nov 12, 2026
- Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in METPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 5, 2019ClinicalTrials.gov NCT03993873 · fetched Nov 12, 2026
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPHASE1_PHASE2 · RECRUITING · started Mar 7, 2017ClinicalTrials.gov NCT03093116 · fetched Nov 12, 2026